Long-term treatment with recombinant insulin-like growth factor 1 (IGF-1) in a child with IGF-1 gene mutation.
We assessed the efficacy and safety of recombinant human insulin-like growth factor 1 (IGF-1) therapy over a period of 7.5 years in a child with severe IGF-1 deficiency. Recombinant human IGF-1 was administered subcutaneously in doses between 40 and 80 microg/kg once daily. Height velocity increased from 2 cm/year on average at baseline to 7.9 cm/year during the first year of treatment. In the following years, growth velocity was less but satisfactory during treatment, but decreased when therapy was stopped.
Concolino
Daniela
D
Department of Pediatrics, University Magna Graecia of Catanzaro, c/o Ospedale Civile A. Pugliese, 88100 Catanzaro, Italy.
Muzzi
Gianluca
G
Sestito
Simona
S
Vega
Giovanna
G
Bonapace
Giuseppe
G
Strisciuglio
Pietro
P
D002648:Child; D004247:DNA / Q000235:genetics*; D004252:DNA Mutational Analysis; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage* / Q000172:deficiency / Q000235:genetics*; D046150:Laron Syndrome / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D009154:Mutation; D011994:Recombinant Proteins / Q000008:administration & dosage*; D013997:Time Factors
D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I; D004247:DNA